NNC0487-0111 for Obesity and Knee Osteoarthritis

(AMAZE 6 Trial)

This trial tests a new treatment called NNC0487-0111, an experimental therapy for individuals with obesity and knee osteoarthritis. The researchers aim to assess the safety and effectiveness of this treatment compared to a placebo, which contains no active medicine. Participants will receive weekly injections and follow a reduced-calorie diet and exercise plan. This trial may suit those who have experienced knee pain from osteoarthritis for at least 90 days and struggle with weight management. As a Phase 3 trial, this treatment is in the final step before FDA approval, providing an opportunity to contribute to its potential availability for wider use.

The trial requires a 72-hour period without taking pain relievers (analgesics) before certain visits, but you can use acetaminophen up to 24 hours before those visits. The protocol does not specify other medication restrictions, so it's best to discuss your current medications with the trial team.

Studies have shown that NNC0487-0111 is generally safe for people with obesity and knee osteoarthritis. Most side effects were mild and manageable. Common issues included nausea and headaches, but these were not severe for most participants. Although this treatment is still under investigation, it has already passed basic safety checks in earlier studies. Overall, evidence suggests that NNC0487-0111 is well-tolerated, with a safety profile similar to other treatments.¹²³⁴⁵

Researchers are excited about NNC0487-0111 because it offers a unique approach to treating obesity and knee osteoarthritis by combining weight management with joint health. Unlike current treatments, which often focus separately on weight loss or joint pain relief, NNC0487-0111 is administered subcutaneously once a week and works as an adjunct to a reduced-calorie diet and increased physical activity. This dual-action potential means it could address both weight and joint issues simultaneously, which is a significant advantage over conventional options like oral medications or joint injections.

Research has shown that NNC0487-0111 might benefit individuals who are overweight and have knee osteoarthritis. In this trial, participants will receive one of two dose levels of NNC0487-0111 or a placebo, administered subcutaneously once weekly alongside a reduced-calorie diet and increased physical activity. Earlier studies found that participants taking NNC0487-0111 lost more weight than those taking a placebo, which contains no active medicine. Weight loss can reduce stress on the knees and may alleviate osteoarthritis symptoms. NNC0487-0111 likely works by affecting hormones that regulate hunger and energy use. Although more information is needed, these results offer promise for those facing these challenges.¹³⁴⁵⁶